Rauch and colleagues provide new insight into tau physiology and potential therapeutic targets for tauopathies: LRP1; the associated lysine residues within the MTBR; and the yet unstudied processes downstream of this LRP1-tau interaction. The gene discussed is LRP1; the disease is tauopathy.